Let the games begin: Novo Nordisk takes the gold in Cowen's 'R&D pentathlon'
While everyone’s tuned into the Olympic Games in Japan, Cowen analysts put drugmakers through a pentathlon of their own — and in terms of R&D execution over the last 10 years, Denmark-based Novo Nordisk $NVO took home the gold.
For the first inaugural R&D games, Cowen set up a series of five challenges: hurdles, or the average time for each company’s agents to reach approval; inactivity, or the next stage of development; the dash, or recruiting speed; the high jump, or R&D efficiency; the long jump, or delay durations; and the shot put, or trial pushouts, defined by whether a delay duration was positive. The firm used data collected on 1,076 drugs from Jan. 1, 2012 to this past March.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.